Nanoform strengthens board with appointment of Vice Chairman
Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has announced the appointment of Miguel Calado as Vice Chairman of the Board. His extensive expertise in strategic business management and finance will strengthen the board and drive Nanoform to further success within international markets, including the US.
Miguel has previously held the position of CFO at Hovione Group, an international particle engineering contract development and manufacturing company. His other previous roles include positions as CFO at PepsiCo International and President International Operations at Dean Foods Corp. Miguel is also an experienced board member with positions on the boards of companies in Europe and the US.
Miguel’s appointment comes at a crucial time in Nanoform’s strategic global expansion, following the employment of four internationally renowned experts in key senior positions of the business in the last six months. Alongside this strengthened commercial organization, Miguel will play an important role in furthering international growth, including expansion into the US market.
Miguel Calado said: “Having spent many years working within the particle engineering industry, I am excited to join the board of Nanoform, a company with game-changing, patent-protected nanonization technology. Their technical prowess is matched by the high calibre of experts within the team. I look forward to helping them ensure success through international growth.”
Edward Hæggström, CEO of Nanoform, said: “I am extremely pleased to welcome Miguel to the Nanoform board. His incomparable experience and strategic vision will enable us to accelerate our goal of providing best-in-class nanonization services to partners across the globe.”
Notes to the Editor
For further information, images and interview opportunities with Nanoform, please contact:
Pranika Sivakumar at Notch Communications
+44 (0) 161 457 7230
Nanoform Finland Limited is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization™ services. The company’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESSᵀᴹ) technology produces nanonized “designed-for-purpose” API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique nanonization™ technology provides novel opportunities in diverse value enhancing drug delivery applications.
For more information please visit http://www.nanoform.fi/